title: [Impact of cytochrome P450 2C19 polymorphisms on outcome of cardiovascular events in clopidogrel-treated Chinese patients after percutaneous coronary intervention].
abstract: OBJECTIVE
  To investigate the impact of cytochrome P450 (CYP) 2C19 681G > A polymorphism on long-term prognosis of clopidogrel-treated Chinese patients after percutaneous coronary intervention (PCI).
  
  
  METHODS
  Between January 1, 2009 and August 31,2009, 267 patients with coronary heart disease who received PCI and treated with clopidogrel for 12 months were enrolled. CYP2C19 * 2 was detected by MALDI-TOF MS and patients were grouped into CYP2C19 * 1/ * 1 (n = 130) and CYP2C19 * 2 carriers group (n = 137). Follow-up was 12 months. The primary endpoint was angina recurrence, urgent coronary revascularization, acute myocardial infarction, stent thrombosis, death and the combined end points.
  
  
  RESULTS
  Baseline data were similar between two groups (P > 0.05). Urgent coronary revascularization and the combined end points occurred more frequently in CYP2C19 * 2 carriers than in CYP2C19 * 1/* 1 patients (7.3% vs. 1.5% and 8.0% vs. 2.3% respectively, all P < 0.05). But incidence of angina recurrence, acute myocardial infarction, stent thrombosis and death was similar between two groups (all P > 0.05). Hazard risk of 1 year cumulative survival of CYP2C19 * 2 carriers group was significantly higher than CYP2C19 * 1/ * 1 group after PCI ( HR = 3.59, 95% CI: 1.02 - 12.87, P < 0.05).
  
  
  CONCLUSIONS
  CYP2C19 681G > A polymorphism is a determinant of prognosis in coronary heart disease patients receiving chronic clopidogrel treatment after PCI.
authors.affiliation: Center of Coronary Heart Disease, Cardiovascular Institute and Fu Wai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China.
authors.forename: Xiao-Fang
authors.initials: XF
authors.lastname: Tang
authors.forename: Chen
authors.initials: C
authors.lastname: He
authors.forename: Jin-Qing
authors.initials: JQ
authors.lastname: Yuan
authors.forename: Xian-Min
authors.initials: XM
authors.lastname: Meng
authors.forename: Yue-Jin
authors.initials: YJ
authors.lastname: Yang
authors.forename: Xue-Wen
authors.initials: XW
authors.lastname: Qin
authors.forename: Shu-Bin
authors.initials: SB
authors.lastname: Qiao
authors.forename: Hai-Bo
authors.initials: HB
authors.lastname: Liu
authors.forename: Yong-Jian
authors.initials: YJ
authors.lastname: Wu
authors.forename: Min
authors.initials: M
authors.lastname: Yao
authors.forename: Jue
authors.initials: J
authors.lastname: Chen
authors.forename: Shi-Jie
authors.initials: SJ
authors.lastname: You
authors.forename: Yuan
authors.initials: Y
authors.lastname: Wu
authors.forename: Jian-Jun
authors.initials: JJ
authors.lastname: Li
authors.forename: Jun
authors.initials: J
authors.lastname: Dai
authors.forename: Ji-Lin
authors.initials: JL
authors.lastname: Chen
authors.forename: Run-Lin
authors.initials: RL
authors.lastname: Gao
authors.forename: Zai-Jia
authors.initials: ZJ
authors.lastname: Chen
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D000077144:Clopidogrel; D003327:Coronary Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics; D065731:Cytochrome P-450 CYP2C19; D005260:Female; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D020641:Polymorphism, Single Nucleotide; D011379:Prognosis; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D013988:Ticlopidine